COSMIC BLUE SHARK (cosmic blue shark transgenic whole- bs2017 rdna constructs not applicable United States - English - NLM (National Library of Medicine)

cosmic blue shark (cosmic blue shark transgenic whole- bs2017 rdna constructs not applicable

glofish llc - cosmic blue shark transgenic whole (bs2017 rdna constructs) (unii: 697vjz6p4y) (cosmic blue shark transgenic whole (bs2017 rdna constructs) - unii:697vjz6p4y) -

COSMIC BLUE DANIO (cosmic blue danio transgenic whole- bzf2010 rdna constructs not applicable United States - English - NLM (National Library of Medicine)

cosmic blue danio (cosmic blue danio transgenic whole- bzf2010 rdna constructs not applicable

glofish llc - cosmic blue danio transgenic whole (bzf2010 rdna constructs) (unii: wlo5t15u8b) (cosmic blue danio transgenic whole (bzf2010 rdna constructs) - unii:wlo5t15u8b) -

COSMIC BLUE TETRA (cosmic blue tetra transgenic whole- bt2014 rdna constructs not applicable United States - English - NLM (National Library of Medicine)

cosmic blue tetra (cosmic blue tetra transgenic whole- bt2014 rdna constructs not applicable

glofish llc - cosmic blue tetra transgenic whole (bt2014 rdna constructs) (unii: bc0b9p42np) (cosmic blue tetra transgenic whole (bt2014 rdna constructs) - unii:bc0b9p42np) -

CABOMETYX 20 MG Israel - English - Ministry of Health

cabometyx 20 mg

medison pharma ltd - cabozantinib as (s) malate - film coated tablets - cabozantinib as (s) malate 20 mg - cabozantinib - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for advanced renal cell carcinoma- as first-line treatment of adult patients with intermediate or poor risk, per imdc criteria.- in adults following prior vascular endothelial growth factor (vegf)-targeted therapy.cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults.hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc), in adults with child-pugh class a hepatic impairment who have previously been treated with sorafenib.differentiated thyroid carcinoma (dtc)cabometyx is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (dtc), refractory or not eligible to radioactive iodine (rai) who have progressed during or after prior systemic therapy.

CABOMETYX 40 MG Israel - English - Ministry of Health

cabometyx 40 mg

medison pharma ltd - cabozantinib as (s) malate - film coated tablets - cabozantinib as (s) malate 40 mg - cabozantinib - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for advanced renal cell carcinoma- as first-line treatment of adult patients with intermediate or poor risk, per imdc criteria.- in adults following prior vascular endothelial growth factor (vegf)-targeted therapy.cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults.hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc), in adults with child-pugh class a hepatic impairment who have previously been treated with sorafenib.differentiated thyroid carcinoma (dtc)cabometyx is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (dtc), refractory or not eligible to radioactive iodine (rai) who have progressed during or after prior systemic therapy.

CABOMETYX 60 MG Israel - English - Ministry of Health

cabometyx 60 mg

medison pharma ltd - cabozantinib as (s) malate - film coated tablets - cabozantinib as (s) malate 60 mg - cabozantinib - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for advanced renal cell carcinoma- as first-line treatment of adult patients with intermediate or poor risk, per imdc criteria.- in adults following prior vascular endothelial growth factor (vegf)-targeted therapy.cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults.hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc), in adults with child-pugh class a hepatic impairment who have previously been treated with sorafenib.differentiated thyroid carcinoma (dtc)cabometyx is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (dtc), refractory or not eligible to radioactive iodine (rai) who have progressed during or after prior systemic therapy.

Dolonac Tablet Bangladesh - English - DGDA (Directorate General of Drug Administration)

dolonac tablet

cosmic pharma ltd. - aceclofenac - tablet - 100 mg

Colaz 400 Tablet Bangladesh - English - DGDA (Directorate General of Drug Administration)

colaz 400 tablet

cosmic pharma ltd. - albendazole - tablet - 400 mg

Colaz Suspension Bangladesh - English - DGDA (Directorate General of Drug Administration)

colaz suspension

cosmic pharma ltd. - albendazole - suspension - 200 mg/5 ml

Alugel Tablet Bangladesh - English - DGDA (Directorate General of Drug Administration)

alugel tablet

cosmic pharma ltd. - aluminium hydroxide + magnesium hydroxide - tablet - 250 mg + 400 mg